A Cholecystokinin Receptor Antagonist Halts Nonalcoholic Steatohepatitis and Prevents Hepatocellular Carcinoma

Robin D. Tucker(Georgetown University), Jill P. Smith(Georgetown University)

Digestive Diseases and Sciences

July 11, 2019

10.1007/s10620-019-05722-3

Cited by 19

Related Papers

Common genetic variants in the CLDN2 and PRSS1-PRSS2 loci alter risk for alcohol-related and sporadic pancreatitis

|Nature Genetics|2012|360

Targeting the Cholecystokinin Receptor: A Novel Approach for Treatment and Prevention of Hepatocellular Cancer

|Cancer Prevention Research|2020|19

Cholecystokinin Receptor Antagonist Improves Efficacy of Chemotherapy in Murine Models of Pancreatic Cancer by Altering the Tumor Microenvironment

|Cancers|2021|14

Vaccination with Polyclonal Antibody Stimulator (PAS) Prevents Pancreatic Carcinogenesis in the KRAS Mouse Model

|Cancer Prevention Research|2021|1